Rohto Pharmaceutical announced that it has received multiple shareholder proposals from two shareholders for the 90th Annual General Meeting of Shareholders scheduled for June 24, 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4527","jir_company_name":"Rohto Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-04-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4527-20260430-01.pdf","jir_short_summary":"Rohto Pharmaceutical announced that it has received multiple shareholder proposals from two shareholders for the 90th Annual General Meeting of Shareholders scheduled for June 24, 2026.","jir_summary":"### Overview of Shareholder Proposals\nRohto Pharmaceutical Co., Ltd. has received shareholder proposal documents from shareholders AVI JAPAN OPPORTUNITY TRUST PLC and LONGCHAMP SICAV in relation to the 90th Annual General Meeting of Shareholders scheduled for June 24, 2026. Shareholder Proposal 1 requests the dismissal of one director. Shareholder Proposal 2 includes seven agenda items: establishment of a strategy review committee, amendments to the Articles of Incorporation regarding the decision-making body for dividends of surplus, share buyback, approval of remuneration amounts under the restricted stock remuneration system, amendments to the Articles of Incorporation concerning the composition of outside directors, amendments to the Articles of Incorporation for management measures mindful of capital costs and stock price, and amendments to the Articles of Incorporation related to the record date for the Annual General Meeting of Shareholders.\n\n### Future Actions and Impact on Investors\nThe Board of Directors will carefully examine and deliberate on the shareholder proposals and disclose decisions promptly once made. These proposals involve important matters related to management structure and capital policy, and depending on the resolutions at the shareholders meeting, may affect management policies and governance framework. Investors should pay close attention to forthcoming disclosures.","jir_financial_highlights":"Number of Proposing Shareholders: 2 (Unknown)\nNumber of Proposals: 7 items (Shareholder Proposal 2) + 1 item (Shareholder Proposal 1) (Unknown)","jir_category":"","jir_hashtags":"#RohtoPharmaceuticalCoLtd, #ShareholderProposals, #GeneralIR","jir_key_figures":"Shareholder Proposal 1: Dismissal of one director (Proposing Shareholder: AVI JAPAN OPPORTUNITY TRUST PLC)\nShareholder Proposal 2: Seven agenda items (Proposing Shareholder: LONGCHAMP SICAV)\nScheduled Date of 90th Annual General Meeting of Shareholders: 2026-06-24","jir_meta_title":"Rohto Pharmaceutical Announces Receipt of Shareholder Proposals\uff5cApril 2026","jir_meta_description":"Rohto Pharmaceutical has received multiple shareholder proposals, including director dismissal and amendments to the Articles of Incorporation, from two shareholders for the upcoming Annual General Meeting in June 2026. Attention is focused on the Board\u2019s future responses.","jir_og_title":"Rohto Pharmaceutical Announces Receipt of Shareholder Proposals\uff5cApril 2026","jir_og_description":"Rohto Pharmaceutical received multiple shareholder proposals from two shareholders, including proposals related to director dismissal and capital policy. Future responses are highly anticipated.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7770,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-44439","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n